Results 131 to 140 of about 4,775,639 (287)

p53 regulates Mevalonate Metabolic pathway

, 2014
2012-2013The mevalonate pathway is an important metabolic pathway implicated in multiple aspects of tumorigenesis. In this study, I provided evidences about genetic and pharmacologic perturbation of p53, which directly influenced expression of mevalonate
D'Alessandro, Alba
core   +1 more source

Corrigendum: Complement activation via the lectin and alternative pathway in patients with severe COVID-19. [PDF]

Front Immunol, 2023
Niederreiter J, Eck C, Ries T, Hartmann A, Märkl B, Buettner-Herold M, Amann K, Daniel C.   +7 more
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

SAR443809: a selective inhibitor of the complement alternative pathway, targeting complement factor Bb. [PDF]

Blood Adv, 2023
Rajagopal V, Leksa N, Gorham R, Jindal S, Nair S, Knockenhauer K, Chan J, Byun T, Mercadante C, Moore S, Panicker S, Parry G, Storek M.   +12 more
europepmc   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Heme Interactions as Regulators of the Alternative Pathway Complement Responses and Implications for Heme-Associated Pathologies. [PDF]

Curr Issues Mol Biol, 2023
Tsiftsoglou SA.
europepmc   +1 more source

... and alternative pathways [PDF]

Nature Reviews Molecular Cell Biology, 2001
openaire   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

The Factor H protein family: The switchers of the complement alternative pathway. [PDF]

Immunol Rev, 2023
Lucientes-Continente L, Márquez-Tirado B, Goicoechea de Jorge E.   +2 more
europepmc   +1 more source

Alternative pathways to low carbon mobility

, 2013
Low carbon mobility is defined as mobility that results in substantially lower levels of carbon consumption and emissions. Here, mobility is defined as the total amount of travel that is undertaken on all forms of transport (Chapter 1), and carbon is used to illustrate the various negative environmental impacts from transport (Chapter 11). As discussed
openaire   +1 more source